GPR18’s immune signature denotes apparent B-cell–T-cell interactions (distinct from MS4A1’s “B-cell only” signature), with its intratumoral expressions tied to major cytolytic T-cell functionality scores across 28 cancers, including the cytolytic/IFN-gamma/T-effector (Teff) signature scores. This evidence concerns the gene GPR18 and cancer.